A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Recruiting

Phase 1

BMS-986488A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Sponsor:

Bristol-Myers Squibb

Code:

NCT06764771

Conditions

Advanced Malignant Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BMS-986488

Adagrasib

Cetuximab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-13. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2025-11-04.